NCT07934069
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of Participants with Adverse Events
Timeframe: From first dose to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Tests
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Vital Signs
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Electrocardiogram Cardiac Conduction Intervals
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Secondary (17)
Parts A and B: Area Under the Concentration Time Curve (AUC) from Time Zero to Last Quantifiable Time (AUClast) of BON-107
Parts A and B: AUC from Time Zero to Infinite Time (AUCinf) of BON-107
Parts A and B: AUC from Time Zero to End of Dosing Interval (AUCtau) of BON-107
Parts A and B: Maximum Observed Plasma Concentration (Cmax) of BON-107
Parts A and B: Time to Maximum Plasma Concentration (Tmax) of BON-107
Show 12 moreShow less
Parts A and B: Trough Plasma Concentration (Ctrough) of BON-107
Parts A and B: Terminal Half-Life (t1/2) of BON-107
Parts A and B: Apparent Drug Clearance (CL/F) of BON-107
Parts A and B: Apparent Volume of Distribution (Vz/F) of BON-107
Part C: AUC from Time Zero to 24 Hours Postdose (AUC0-24) of BON-107
Part C: AUClast of BON-107
Part C: AUCinf of BON-107
Part C: Cmax of BON-107
Part C: Tmax of BON-107
Part C: t1/2 of BON-107
Part C: CL/F of BON-107
Part C: Vz/F of BON-107
Arms and interventions
Part A: Single Ascending Doses (SAD) of BON-107Experimental
Sequential cohorts of healthy participants will receive a single dose of BON-107 at increasing dose levels.
Part A: PlaceboPlacebo comparator
Sequential cohorts of healthy participants will receive a single dose of matching placebo.
Part B: Multiple Ascending Doses (MAD) of BON-107Experimental
Sequential cohorts of healthy participants will receive multiple doses of BON-107 at increasing dose levels.
Part B: PlaceboPlacebo comparator
Sequential cohorts of healthy participants will receive multiple doses of matching placebo.
Part C: Food Effect of BON-107Experimental
Healthy participants will take BON-107 in a fed and fasted state, with a washout period between.
Drugs: BON-107, Placebo